Sanofi exec joins Emergex Vaccines as chief medical officer

UK-based biotech firm Emergex Vaccines today announces the appointment of Athanasios Papadopoulos as chief medical officer, effective March 1, 2019. Dr Papadopoulos will report directly to Emergex’ chief executive Professor Thomas Rademacher.

In his new role Dr Papadopoulos will use his extensive medical, regulatory and clinical development expertise to provide leadership and direction on the development of Emergex’ growing pipeline of vaccines.

Dr Papadopoulos joins Emergex from French pharma major Sanofi (Euronext: SAN), the where he was most recently associate vice president, senior director and clinical franchise leader of global clinical sciences since 2015. During his time at Sanofi, Dr Papadopoulos played a critical role in the development of Dengvaxia, the first vaccine approved for Dengue fever.